Emerald Mutual Fund Advisers Trust Buys 8,079 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Emerald Mutual Fund Advisers Trust boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 3.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,399 shares of the company’s stock after purchasing an additional 8,079 shares during the period. Mirum Pharmaceuticals comprises 1.1% of Emerald Mutual Fund Advisers Trust’s investment portfolio, making the stock its 22nd largest position. Emerald Mutual Fund Advisers Trust owned 0.41% of Mirum Pharmaceuticals worth $23,132,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Faithward Advisors LLC grew its holdings in shares of Mirum Pharmaceuticals by 0.5% in the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock worth $2,537,000 after purchasing an additional 126 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after buying an additional 200 shares during the period. Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares during the period. Finally, Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $30,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the transaction, the senior vice president owned 3,114 shares in the company, valued at approximately $373,680. This represents a 46.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.27, for a total value of $2,445,400.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. The trade was a 9.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 65,315 shares of company stock valued at $6,991,928. 8.32% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MIRM. HC Wainwright reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a report on Monday, June 15th. TD Cowen upped their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wall Street Zen cut Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $143.40.

Mirum Pharmaceuticals Trading Down 2.5%

NASDAQ:MIRM opened at $119.04 on Tuesday. The company has a 50-day moving average price of $106.93 and a 200-day moving average price of $98.12. The stock has a market cap of $7.26 billion, a price-to-earnings ratio of -8.75 and a beta of 0.48. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12 month low of $50.25 and a 12 month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.